Back to News
Market Impact: 0.3
Raymond James Initiates Coverage of Quince Therapeutics at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Raymond James initiated coverage of Quince Therapeutics with an Outperform recommendation on October 9, 2026. The stock closed at $31.73 that day, compared with $29.36 on October 8; the article does not attribute the price difference to the rating.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
QNCX0.55
More News
- Trading expert sets date when Micron (MU) stock will crash to $400
- Merck’s remigromig meets non-inferiority goal in DME trial
- Bank of America is bullish on these top stocks ahead of earnings
- Strong Earnings Keep US Stocks in Favor
- JPMorgan makes bullish call in fixed income space, suggests it's a once in a generation opportunity
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off